Neuland Laboratories News, Corporate filings and Earnings/Conference Calls

Pharmaceuticals company Neuland Laboratories announced Q1FY27 results Consolidated Financial Highlights: Revenue from operations in Q1FY27 stood at Rs 64,157.71 lakh, marking a significant YoY growth of 119.15% from Rs 29,275.27 lakh in Q1FY26. On a QoQ basis, revenue decreased by 17.35% from Rs 77,625.03 lakh in Q4FY26. Total income for the quarter was Rs 65,006.88 lakh in Q1FY27, reflecting a YoY increase of 116.25% from Rs 30,060.86 lakh and a QoQ decline of 17.58% compared to Rs 78,870.85 lakh in Q4FY26. Profit before tax reached Rs 19,784.70 lakh in Q1FY27, showing a YoY growth of 1,026.03% from Rs 1,757.04 lakh in Q1FY26. Sequentially, it saw a decrease of 31.18% from Rs 28,749.48 lakh in Q4FY26. Net profit for the period stood at Rs 14,767.31 lakh in Q1FY27, a YoY growth of 962.40% from Rs 1,390.00 lakh in Q1FY26. On a sequential basis, net profit declined by 30.56% from Rs 21,267.26 lakh in Q4FY26. Total comprehensive income was Rs 14,758.41 lakh in Q1FY27, compared to Rs 1,399.92 lakh in Q1FY26 (YoY growth of 954.22%) and Rs 21,390.92 lakh in Q4FY26 (QoQ decline of 31.01%). Earnings per share (Basic and Diluted) was Rs 115.10 for Q1FY27, compared to Rs 10.83 in Q1FY26 and Rs 165.76 in Q4FY26. Standalone Financial Highlights: Revenue from operations for Q1FY27 was Rs 64,157.71 lakh, up 119.15% YoY from Rs 29,275.27 lakh and down 17.35% QoQ from Rs 77,625.03 lakh in Q4FY26. Total income stood at Rs 65,006.88 lakh in Q1FY27, up 116.25% YoY and down 17.58% QoQ. Net profit for the period was Rs 14,736.19 lakh in Q1FY27, marking a YoY growth of 975.04% from Rs 1,370.76 lakh in Q1FY26 and a QoQ decline of 30.66% from Rs 21,252.31 lakh in Q4FY26. Business Highlights Manufacturing Capacity Enhancement: The company approved the enhancement of manufacturing capacity at Unit 1 (Bonthapally Village, Telangana). The proposed addition is 18 KL to the existing 376.5 KL capacity. The investment required is Rs 39.8 crore (including GST), to be financed through internal accruals with an estimated completion period of 6 to 7 months. Corporate Guarantee: The Board approved the execution of a corporate guarantee for Rs 40 crore in favour of Gland Pharma Limited. This is in connection with a Loan Licence Agreement to establish dedicated manufacturing capacity and incur capital expenditure for the manufacture of certain products. Strategic Collaboration: The company announced a long-term strategic CDMO partnership with Gland Pharma Limited to expand sterile API manufacturing. Gland Pharma will establish a dedicated sterile manufacturing suite at its Visakhapatnam facility to support the company's growing demand, adding approximately 1,400 kg of annual capacity. Segment-wise Performance (Geographical): India: Revenue was Rs 8,326.38 lakh in Q1FY27 compared to Rs 9,892.62 lakh in Q1FY26. Europe: This region contributed the highest revenue at Rs 30,345.81 lakh in Q1FY27, up from Rs 9,441.22 lakh in Q1FY26. USA and North America: Revenue stood at Rs 19,967.36 lakh in Q1FY27 compared to Rs 6,578.38 lakh in Q1FY26. Rest of the World: Revenue was Rs 5,518.16 lakh in Q1FY27 compared to Rs 3,363.05 lakh in Q1FY26. Saharsh Davuluri, CEO & MD, Neuland Laboratories, said: "Demand for sterile APIs continues to grow as pharmaceutical companies advance increasingly complex injectable therapies. Through this partnership with Gland Pharma, we are combining Neuland's expertise in complex APIs with Gland's proven sterile manufacturing capabilities to create a differentiated platform for global customers. Together, we are strengthening our ability to deliver the quality, reliability, and supply assurance that innovators and generic companies expect from their COMO partners." Srinivas Sadu, Executive Chairman, Gland Pharma, said: "We are pleased to further strengthen our collaboration with Neuland through this strategic partnership. This investment expands our capabilities in sterile API manufacturing and supports increasing customer demand. By leveraging the complementary strengths of both organizations, we will provide a robust and scalable COMO solution backed by world-class quality, compliance and manufacturing excellence. We believe this partnership creates a strong foundation for sustainable growth and long-term value creation for our customers and both organizations." Result PDF

New 52W High in past week

High vol.+gain this week

Neuland Laboratories News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Neuland Laboratories from all sources in a single place.